Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Kanova logo — Pioneering advanced therapies in immuno-oncology and autoimm...

Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases.

Founded 2015 2-10 employees Series B Total: $215.00M Biopharma, Health and Wellness +1

General Information

Company Name Kanova
Founded Year 2015
Employees 2-10
Industries Biopharma, Health and Wellness, Pharmaceutical
Funding Stage Series B
Social

Get notified when Kanova moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Kanova

Kanova is a biopharmaceutical company founded in 2015 that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases. The company's slogan, "Pioneering advanced therapies in immuno-oncology and autoimmune diseases," reflects its commitment to cutting-edge medical solutions. In its latest funding round, Kanova secured a significant CNY100.00M Series B investment on 25 July 2023. The investment was led by prominent venture capital firms including Northern Light Venture Capital, Tsinghua Venture Capital, CD Capital, Life Garden Venture Capital, Yangzhou Fengsheng Investment, and ShenZhen GTJA Investment Group. With its focus on the biopharma, health and wellness, and pharmaceutical industries, Kanova is positioned for growth and innovation in the rapidly evolving field of medical therapeutics.

Taxonomy: biopharmaceutical, therapeutic antibodies, immuno-oncology, autoimmune diseases, advanced therapies, immunotherapy, oncology, cancer treatment, immunology, drug development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor
•••• •••• 		25 Jul 2023
Series B •••••• 4
Investor Investor Investor Investor
13 Jul 2021
Series A •••••• - 26 Nov 2018

Kanova Alternatives & Competitors

Kanova vs
Willamette Valley Cancer Institute & Research Center
Willamette Valley Cancer Institute & Research Center United States

We offer hope. We guide and navigate. We are our patients' strongest advocates.

113 employees
Health Care, Health and Wellness
Kanova vs
ESMO - European Society for Medical Oncology
ESMO - European Society for Medical Oncology Switzerland

A reference for oncology education and information

427 employees
Health Care
Kanova vs
S C Oncology
S C Oncology

South Carolina Oncology Associates (SCOA) is the only comprehensive cancer treatment center in South...

15 employees
Health Care

FAQ About Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases.
Kanova was founded in 2015.
Kanova operates in the following industries: Biopharma, Health and Wellness, Pharmaceutical.
Kanova has approximately 2-10 employees.
Kanova has completed 3 funding rounds, raising a total of $215.00M. The latest funding stage is Series B.
Top alternatives and competitors to Kanova include Willamette Valley Cancer Institute & Research Center, ESMO - European Society for Medical Oncology, S C Oncology, Cumulus Oncology, Champions Oncology, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kanova and Willamette Valley Cancer Institute & Research Center are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Kanova and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy